Barclays analyst Carter Gould maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) today and set a price target of $975.00.

The trial met both primary endpoints, with tirzepatide showing a 38% decrease in heart failure outcomes compared to placebo.

The makers of Ozempic and Zepbound are fighting to stop compounded copies of their drugs. But it’s unclear whether they can ...

State Medicaid programs for low-income families are the single biggest source of coverage, giving 31.6 million people access ...

The drugmaker Ely Lilly ( LLY -4.93%) has had a very successful run over the long run. Shares currently trade around $818 and are up 20,030% over the past 40 years. The stock has also performed well ...

Novo Nordisk and Eli Lilly are facing scores of personal injury claims for allegedly failing to warn patients about side ...

U.S. government health plans account for the lion's share of coverage for popular new weight-loss drugs, far beyond the ...

From a travel agency battling COVID blues and an investment firm licking its wounds, to a Spanish company with a network ...

Novo Nordisk has long supplied human insulin pens to the national health department. But last year it decided not to bid for ...

Indiana University analysis suggests that aggregate health care spending in the state is on par with peers in other states, but that Hoosiers are more likely ...

The State of Indiana won’t pay property taxes for 9,000 acres it has bought in Boone County because state and non-profit ...

CHICAGO -- Researchers failed to prevent cognitive impairment in people with existing atrial fibrillation (Afib) by going the ...